Compare Main Street Capital Corporation (MAIN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Main Street Capital Corporation trades at $58.78 (market cap $5.52B), while State Street SPDR S&P Biotech ETF trades at $159.79. The key difference: Main Street Capital Corporation pays a 5.39% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Main Street Capital Corporation nearer its low. Which is the better fit depends on your goals.
| MAIN | XBI | |
|---|---|---|
Market Cap | $5.52B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $67.54 | $164.28 |
52-Week Low | $49.63 | $86.92 |
Dividend Yield | 5.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $59.10, up 0.99% with a bullish technical outlook. The stock shows strong fundamentals with an 80.77% net income margin and 14.92% ROE, though Q2 2026 earnings missed estimates. Recent news highlights MAIN's dividend reliability amid sector challenges, with the company maintaining payouts while peers face cuts. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $59-60.
MAIN offers stable income with consistent dividends but faces headwinds from declining revenue projections ($592M in 2025 to $559M in 2026). Analyst consensus is cautious with 78.57% hold ratings and a $56.67 price target below current levels. Key risks include BDC sector pressure and expense growth impacting earnings coverage.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
